» Articles » PMID: 20071513

Olfactory Dysfunction Correlates with Amyloid-beta Burden in an Alzheimer's Disease Mouse Model

Overview
Journal J Neurosci
Specialty Neurology
Date 2010 Jan 15
PMID 20071513
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease often results in impaired olfactory perceptual acuity-a potential biomarker of the disorder. However, the usefulness of olfactory screens to serve as informative indicators of Alzheimer's is precluded by a lack of knowledge regarding why the disease impacts olfaction. We addressed this question by assaying olfactory perception and amyloid-beta (Abeta) deposition throughout the olfactory system in mice that overexpress a mutated form of the human amyloid-beta precursor protein. Such mice displayed progressive olfactory deficits that mimic those observed clinically-some evident at 3 months of age. Also, at 3 months of age, we observed nonfibrillar Abeta deposition within the olfactory bulb-earlier than deposition within any other brain region. There was also a correlation between olfactory deficits and the spatial-temporal pattern of Abeta deposition. Therefore, nonfibrillar, versus fibrillar, Abeta-related mechanisms likely contribute to early olfactory perceptual loss in Alzheimer's disease. Furthermore, these results present the odor cross-habituation test as a powerful behavioral assay, which reflects Abeta deposition and thus may serve to monitor the efficacy of therapies aimed at reducing Abeta.

Citing Articles

Beyond anosmia: olfactory dysfunction as a common denominator in neurodegenerative and neurodevelopmental disorders.

Chen Y, Kostka J Front Neurosci. 2024; 18:1502779.

PMID: 39539496 PMC: 11557544. DOI: 10.3389/fnins.2024.1502779.


NEGR1 Modulates Mouse Affective Discrimination by Regulating Adult Olfactory Neurogenesis.

Kim K, Noh K, Lee J, Lee S, Lee S Biol Psychiatry Glob Open Sci. 2024; 4(5):100355.

PMID: 39170714 PMC: 11338060. DOI: 10.1016/j.bpsgos.2024.100355.


ErbB4 deficiency exacerbates olfactory dysfunction in an early-stage Alzheimer's disease mouse model.

Deng X, Liu X, Wei Y, Wang K, Zhu J, Zhong J Acta Pharmacol Sin. 2024; 45(12):2497-2512.

PMID: 38982150 PMC: 11579518. DOI: 10.1038/s41401-024-01332-6.


Aβ and ROS dual-targeted multifunctional nanocomposite for combination therapy of Alzheimer's disease.

Zhang L, Cao K, Xie J, Liang X, Gong H, Luo Q J Nanobiotechnology. 2024; 22(1):278.

PMID: 38783363 PMC: 11112798. DOI: 10.1186/s12951-024-02543-z.


Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease.

Sepulveda-Falla D, Velez J, Acosta-Baena N, Baena A, Moreno S, Krasemann S Alzheimers Dement. 2024; 20(4):2873-2885.

PMID: 38450831 PMC: 11032577. DOI: 10.1002/alz.13754.


References
1.
Reisert J, Matthews H . Response properties of isolated mouse olfactory receptor cells. J Physiol. 2001; 530(Pt 1):113-22. PMC: 2278387. DOI: 10.1111/j.1469-7793.2001.0113m.x. View

2.
Varvel N, Bhaskar K, Patil A, Pimplikar S, Herrup K, Lamb B . Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci. 2008; 28(43):10786-93. PMC: 2680286. DOI: 10.1523/JNEUROSCI.2441-08.2008. View

3.
Lee V, Goedert M, Trojanowski J . Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24:1121-59. DOI: 10.1146/annurev.neuro.24.1.1121. View

4.
Gao Y, Pimplikar S . The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A. 2001; 98(26):14979-84. PMC: 64969. DOI: 10.1073/pnas.261463298. View

5.
Montgomery K, Simmons R, Edwards 3rd G, Nicolle M, Gluck M, Myers C . Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: implications for translational research. Neurobiol Aging. 2009; 32(7):1273-85. PMC: 4334376. DOI: 10.1016/j.neurobiolaging.2009.08.003. View